acetohydroxamic acid
Approved
May 31, 1983
Acetohydroxamic acid (also known as AHA or by the trade name Lithostat) is a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. Acetohydroxamic acid is used to lower the level of ammonia in the urine, which may help with some types of urinary infections. Acetohydroxamic Acid has no direct antimicrobial action and does not acidify urine directly. It is used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections. In 1983 the US Food and Drug Administration approved acetohydroxamic acid (AHA) as an orphan drug for "prevention of so-called struvite stones" under the newly enacted Orphan Drug Act of 1983. — NCATS
Clinical trial activity
2 trials · 2 clinical orgs · 1 marketing orgs
Earliest trial started Nov 1, 2016 (NCT02670889)
Timeline
1980s
- May 31, 1983
Mission Pharmacal — Earliest FDA Approval
- May 31, 1983
Mission Pharmacal — NDA Organization
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Bacterial ureaseINHIBITOR
Bacterial urease inhibitor
Approval history
- approvedPriority reviewMay 31, 1983
Chemistry & pharmacology
SMILES
CC(=O)NO- Mol. weight
- 75.0666 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaAcetohydroxamic acid ↗
- NCATS4RZ82L2GY5 ↗
- ChEMBLCHEMBL734 ↗
Also known as
- acethydroxamsaeure
- acethydroxamsaeure
- acethydroxamsaure
- acethydroxamsaure
- acetic acid, oxime
- acetic acid, oxime
- acetohydroxamate
- acetohydroxamate
- acetohydroxamate
- acetohydroxamic acid
- acetohydroxamic acid
- acetohydroxamic acid
- acetohydroxamic acid
- acetohydroxamic acid
- acetohydroxamic acid
- acetohydroxamic acid
- acetohydroxamic acid
- acetohydroxamic acid
- acetohydroxamic acid
- acetohydroximic acid
- acetohydroximic acid
- acetohydroximic acid
- acetylhydroxamic acid
- acetylhydroxamic acid
- acetylhydroxamic acid
- acetyl hydroxyamino
- acetyl hydroxyamino
- acide acetohydroxamique
- acide acetohydroxamique
- acido acetohidroxamico
- acido acetohidroxamico
- acidum acetohydroxamicum
- acidum acetohydroxamicum
- aha
- aha
- cetohyroxamic acid
- cetohyroxamic acid
- lithostat
- lithostat
- lithostat
- lithostat
- methylhydroxamic acid
- methylhydroxamic acid
- mission brand of acetohydroxamic acid
- n-acetyl hydroxyacetamide
- n-acetyl hydroxyacetamide
- n-acetyl hydroxyacetamide
- n-acetylhydroxylamine
- n-acetylhydroxylamine
- n-acetylhydroxylamine
- n-hydroxyacetamide
- n-hydroxyacetamide
- n-hydroxyacetamide
- n-hydroxyacetamide
- n-hydroxyacetamidine
- robert brand of acetohydroxamic acid
- uronefrex
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03181828 | Phase 1/Phase 2 (Phase 2) | Mar 24, 2017 | Children's National Medical Center |
| NCT02670889 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2016 | Children's National Medical Center, University of Pennsylvania |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Children's National Medical Center | Academic/Hospital | 2 | 2 | 1 | 2016 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2016 |
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Mission Pharmacal | For profit | NDA | May 31, 1983 |